« Previous
Next »
Fertility and Sterility
Volume 91, Issue 5
, Pages 1646-1653
, May 2009
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials
References
- . Risk-benefit effects of implantable contraceptives in women. Expert Opin Drug Safety. 2003;2:321–332
- . A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum Reprod. 1999;14:976–981
- . The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 1986;34:253–260
- . Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005;84:207–216
- . Advances in female hormonal contraception: current alternatives to oral regimens. Treat Endocrinol. 2003;2:247–256
- Hormonal contraception update. Mayo Clin Proc. 2006;81:949–954
- . Contraceptive failure in the United States. Contraception. 2004;70:89–96
- National Institute for Health and Clinical Excellence. Long acting reversible contraception. Clinical guideline 30. October 2005. Available at: http://guidance.nice.org.uk/CG30/guidance/pdf/English. Accessed April 13, 2007.
- . The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Contraception. 1996;174:1161–1170
- . Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception. 2005;71:306–308
- . Ultrasound localisation of nonpalpable Implanon. Aust N Z J Obstet Gynaecol. 2005;45:112–116
- . The significance of bleeding patterns in Norplant implant users. Obstet Gynecol. 1991;77:256–260
- . Contraception-associated menstrual problems: etiology and management. Dialogues Contraception. 1998;5:1–6
- . A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60:1–8
Supported by Organon.
Dr. Darney has received research funding from Organon and has served as an advisor to Organon. Dr. Patel has served on the Speakers' Bureau for Organon. Dr. Kaunitz has received research funding from Barr, Bayer, Organon, and Warner-Chilcott and has served as a speaker and/or consultant for the American College of Obstetricians and Gynecologists, Barr, Bayer, Johnson and Johnson, Organon, and Warner-Chilcott. Dr. Rosen has nothing to disclose. D. Shapiro has nothing to disclose.
PII: S0015-0282(08)00515-3
doi: 10.1016/j.fertnstert.2008.02.140
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Fertility and Sterility
Volume 91, Issue 5
, Pages 1646-1653
, May 2009

